While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...

The safety profile of the therapy was found to be favourable, without any serious adverse events linked to the treatment.

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...

Vertex Pharmaceuticals (NASDAQ:VRTX) has posted new data from a Phase 1/2/3 study for zimislecel (VX-880), its experimental ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big PBMs to cover the non-opioid pain drug. In what analysts called a “sticker ...

In this paper, we develop a vertex-to-edge weighted closed-form algorithm to reduce camera drift for dense RGB-D indoor simultaneous localization and mapping (SLAM). First, due to the high-frame rate ...

Goldman Sachs analyst reiterates Buy on Vertex, with a $48 target, expecting strong, sustainable growth and macro resilience. Analyst anticipates focus on demand sustainability, e-invoicing ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

You can reach Jonathan on Signal at jwosen.27. Vertex Pharmaceuticals on Thursday won approval from the Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of ...

Vertex’s reconfiguration of the hydrocracker marks the first project by any operator taking on a flexible conventional-to-renewable unit conversion in recent years to return such a unit to its ...